“Kris’s patent prosecution expertise, training as a molecular biologist and deep experience advising both innovators and investors on intellectual property matters perfectly complement our Life Sciences practice, clients’ needs and areas of expected growth,” said Mitchell Bloom, global chair of Goodwin’s Life Sciences practice. “Adding high-caliber intellectual property talent like Kris is vital as we continue to build Goodwin’s global life sciences bench strength and bolster our capabilities at the intersection of innovation and capital.”
Bieker focuses on strategic patent portfolio development for early-stage life sciences companies and their investors, and on intellectual property matters during financings, public offerings, mergers and strategic partnerships. With a PhD in molecular biology, Bieker represents both private and public biotech, pharmaceutical and medical device companies on matters relating to the design, life-cycle exclusivity strategies, patent prosecution, including patentability, non-infringement and invalidity opinions, licensing, joint development agreements, and patent enforcement. In addition, she performs IP due diligence on potential investments for some of the top venture capital firms and serial entrepreneurs in the world.
Bieker received her JD from Boston College Law School, a PhD in Molecular Biology and MA in Biology from Princeton University, and BA in Biology from Swarthmore College.
Bieker can be reached at firstname.lastname@example.org and 617.570.1207.
Goodwin represents leading public and private life sciences companies and investors across their entire life cycles – including financings, capital market transactions, mergers and acquisitions, collaborations and licensing, intellectual property and regulatory matters. Goodwin has been named life sciences “Practice Group of the Year” by Law360, “ Biotech Firm of the Year” by U.S. News and World Report - Best Lawyers for five years, and “IP Law Firm of the Year” and “Life Cycle Firm of the Year” by LMGLife Sciences.